A rare case of prostatic malakoplakia with multidrug-resistant Escherichia coli: a case report

BMC Infect Dis. 2024 Oct 31;24(1):1226. doi: 10.1186/s12879-024-10144-2.

Abstract

Prostatic malakoplakia is an uncommon chronic inflammatory disorder, tumor-like but non-cancerous, the diagnosis of which pivots crucially on the identification of characteristic Michaelis-Gutmann bodies within the pathological tissue. We hereby present an inaugural case report of prostatic malakoplakia concurrent with sepsis caused by multidrug-resistant Escherichia coli, verified through blood culture and metagenomic next-generation sequencing (mNGS). The pathogenesis might be associated with infections by Escherichia coli, immune system irregularities, or lysosomal dysfunction. Although the patient had no chronic underlying diseases, he presented early with sepsis and multi-organ dysfunction. This case emphasizes the imperative to further investigate the association between malakoplakia and Escherichia coli, the necessity for prompt diagnosis, and the supportive role of mNGS, and the treatment strategy focuses on rapid control of infection and systemic inflammatory response.

Keywords: Escherichia coli; Malakoplakia; mNGS.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial*
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / microbiology
  • Escherichia coli* / drug effects
  • Escherichia coli* / genetics
  • Escherichia coli* / isolation & purification
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Malacoplakia* / drug therapy
  • Malacoplakia* / microbiology
  • Prostate / microbiology
  • Prostate / pathology
  • Prostatic Diseases / drug therapy
  • Prostatic Diseases / microbiology
  • Sepsis / drug therapy
  • Sepsis / microbiology

Substances

  • Anti-Bacterial Agents